Intravenous anti-D immune globulin-induced intravascular hemolysis in Epstein-Barr virus-related thrombocytopenia.
RhoD immune globulin intravenous (anti-D IGIV) increases platelet counts in patients who have not undergone splenectomy and are positive for RhoD with idiopathic thrombocytopenic purpura. After treatment, in most patients, anemia develops as a result of immune-mediated red cell destruction in the spleen. Although intravascular hemolysis (IVH) is not expected, life-threatening IVH has been recently reported by the Food and Drug Administration, and physicians are encouraged to report their experience with patients with idiopathic thrombocytopenic purpura in whom IVH develops after anti-D administration. Severe IVH was observed after treatment with anti-D IGIV in two adolescent girls with acute thrombocytopenia related to Epstein-Barr virus. They did not have hemolytic anemia before treatment. The authors believe that anti-D IGIV triggered an unusual virus-induced immune response causing hemolysis; therefore, anti-D IGIV should not be used in patients with Epstein-Barr virus-related thrombocytopenia, particularly during the acute phase of infection.
Levendoglu-Tugal
O
O
New York Medical College, Department of Pediatrics, Valhalla 10595, USA.
Jayabose
S
S
D000293:Adolescent; D000743:Anemia, Hemolytic / Q000139:chemically induced*; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D006461:Hemolysis; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000209:etiology* / Q000628:therapy; D018029:Rho(D) Immune Globulin / Q000009:adverse effects*
D016756:Immunoglobulins, Intravenous; D018029:Rho(D) Immune Globulin